Talc lawyer says J&J's multibillion-dollar stock woes make settling look like a better deal

Johnson & Johnson faces about 11,700 lawsuits alleging harm from talc, according to a recent securities filing. (J&J)

What's bad for Johnson & Johnson shares is good for the trial lawyer leading the charge in the talc liability litigation—or so the lawyer says, as J&J scrambles to contain the damage from a bombshell Reuters report Friday.

After the news service said J&J had hidden asbestos it found in some talc samples, a massive selloff took $40 billion off the company's shares. And as J&J and its CEO countered the news coverage, plaintiffs' lawyer Mark Lanier told CNBC that the selloff strengthened his hand.

Think of it as the liability litigator's version of a stock-shorting report. Lanier served as one of Reuters' sources and provided photos for its story, whose allegations J&J has vociferously denied. And this week, after the stock plummeted, Lanier told the news outlet that the market-cap loss makes settling the litigation more attractive.

The company's talc “problems can be resolved for much, much less than” the tens of billions J&J lost in market value, said Lanier, who led the team that secured a massive $4.69 billion talc verdict against J&J this summer. The company has since appealed.

It “serves my purposes as a litigator to say, ‘Yes, get their attention; keep driving the stock down,'" Lanier said during the interview.

Indeed, on Friday, J.P. Morgan analyst Chris Schott assessed the 10% stock drop as an “over-reaction” because J&J’s potential talc liability won’t come close to the company’s lost market value, which was about $40 billion at the time.

RELATED: J&J stock tumbles after Reuters reports it hid asbestos in talc 

Reuters' Friday report, based on court documents filed on both sides of the contentious litigation, said that J&J had found asbestos in some talc samples from the 1970s to the 2000s. J&J, for its part, says Reuters “misrepresented J&J, our product, our actions, and the science about talc.” The company argues that Reuters “misled its readers by printing inaccurate statements [and] withholding crucial information that otherwise undermines its thesis.”

J&J took its argument to consumers on Monday in the form of an ad in major print and online news publications, and CEO Alex Gorsky rebuffed the allegations in a company-made video. 

“We know that our talc is safe,” Gorsky said in the video. “In fact, for over 100 years, Johnson & Johnson has known that the talc in our baby powder, is the purest, safest, pharmaceutical grade talc on earth.” If J&J believed the product was unsafe, it would be “off the shelves and out of the market immediately," he said.

RELATED: What to do when an exposé tanks your stock? For J&J, you go direct to consumers

J&J has been defending its key product for several years against thousands of lawsuits alleging the product causes ovarian cancer and mesothelioma. Although the powder isn’t a huge revenue source for the healthcare conglomerate, it’s closely tied with J&J’s image. So far, the company has suffered several multimillion-dollar losses in court, but in many instances, J&J has been able to overturn the verdicts on appeal. 

In a trial combining the claims of 22 women represented by Lanier, this summer J&J  suffered its biggest defeat yet in the form of a $4.6 billion jury verdict.

Along with other recent developments, authorities in India on Wednesday launched an investigation into talc safety, Reuters reports.

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.